SCHEMBL25972203

SCHEMBL25972203

CC(C)(C)OC(=O)Cc1cnccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.39
IDO1 P14902 1/20 0.39
CCNB2 O95067 1/20 0.38
CCNE2 O96020 1/20 0.38
CDK1 P06493 1/20 0.38
CDK4 P11802 1/20 0.38
CCNB1 P14635 1/20 0.38
CCND1 P24385 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
MTNR1A P48039 4/20 0.38
MTNR1B P49286 4/20 0.38
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 1/20 0.36
SYK P43405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7450027 0.84 GPR119 (0.38) GPR119CCNB2CCNE2CDK1CDK4
SCHEMBL29798883 0.81 HDAC3 (0.43) IDO1HDAC3HDAC1HDAC2HDAC6
SCHEMBL5306141 0.81 HDAC3 (0.43) IDO1HDAC3HDAC1HDAC2HDAC6
SCHEMBL4086758 0.78 IDO1 (0.44) IDO1HDAC3HDAC1HDAC2HDAC6
SCHEMBL11680189 0.78 SMN1; SMN2 (0.46) IDO1KDM4EALDH1A1RAB9ANPC1
SCHEMBL28788425 0.77 IDO1 (0.41) IDO1HDAC3HDAC1HDAC2HDAC6
SCHEMBL10389581 0.77 KDM4E (0.42) IDO1HDAC3HDAC1HDAC2HDAC6
SCHEMBL6339719 0.77 ALDH1A1 (0.51) IDO1KDM4EALDH1A1TSHRRAB9A
SCHEMBL29676749 0.77 ALDH1A1 (0.51) IDO1KDM4EALDH1A1TSHRRAB9A
SCHEMBL1265671 0.76 NAMPT (0.48) HDAC3HDAC1HDAC2HDAC6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease RIPK1, RIPK2, RIPK4 GPR119 550/4885IDO1 3786/4885CCNB2 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.